NOVEL AVERMECTINS PRODUCED BY MUTATIONAL BIOSYNTHESIS
NOVEL AVERMECTINS PRODUCED BY MUTATIONAL BIOSYNTHESIS
复制标题
DOI：
10.7164/antibiotics.44.357
复制
发表时间：
1991-03-01
影响因子：
3.3
通讯作者：
RICHARDS, MK
中科院分区：
文献类型：
--
作者：
DUTTON, CJ;GIBSON, SP;RICHARDS, MK
通过向阿维链霉菌突变株atcc 53568添加羧酸或其生物合成前体，制备了具有多种新型C-25取代基的阿维菌素。该菌缺乏从2-氧代酸前体生成异丁酸和S-2-甲基丁酸的能力，因此除非供应这些酸，否则不能产生天然的阿维菌素。通过突变生物合成产生的新型阿维菌素具有广谱的抗寄生虫活性。
Avermectins with a wide range of novel C-25 substituents have been prepared by feeding carboxylic acids or their biosynthetic precursors to a Streptomyces avermitilis mutant strain ATCC 53568. This organism lacks the ability to form isobutyric and S-2-methylbutyric acids from their 2-oxo acid precursors and thus is unable to produce natural avermectins unless supplied with these acids. The novel avermectins produced by mutational biosynthesis possess broad-spectrum antiparasitic activity.